Cs-4 and Cultured Cordyceps Mycelium
Cs-4 is a lab-grown fungus (Paecilomyces hepiali) fermented in tanks and sold as Jinshuibao and "Cordyceps" supplements; here is what it is, what the mostly Chinese trials show, and what is not known about its safety and quality.
Content last updated . This page has not been medically reviewed.

Safety first. Supplements can cause side effects and interact with medicines. Read mushroom safety and interactions before you use any mushroom product.
Documented analytical data
Each group below is one study's measurement of the stated specimen or preparation. It is not a typical value for the species or product, varies between specimens, and says nothing about effects or safety. 6 values from 6 sources.
He M, Tang CY, Wang T, Xiao MJ, Li YL, Li XZ. Analysis of metabolic profiles and antioxidant activity of Chinese cord... (1 value)
Source: He M, Tang CY, Wang T, Xiao MJ, Li YL, Li XZ. Analysis of metabolic profiles and antioxidant activity of Chinese cordyceps, Ophiocordyceps sinensis, and Paecilomyces hepiali based on untargeted metabolomics. Biology (Basel) 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11428516/. Open access. Laboratory: Lab of He M et al., China. Method: FRAP kit assay (Suzhou Keming), 100 mg/mL extract. Date: 2024 paper.
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Jinshuibao (P. hepiali) bought from pharmacies, one sample | FRAP total antioxidant capacity | 8.26 micromole Trolox per g (dried powder, test-tube assay) | reported value (reported) | not stated. one product, one manufacturer or one purchased sample |
Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Comp... (1 value)
Source: Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Complement Altern Med 2019;19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6441223/. Open access; values as cited by the authors from earlier work. Laboratory: Korean manufacturer's analysis, reported in the paper. Method: HPLC per Korean food regulator guidelines, as stated. Date: 2019 paper (maker's earlier work cited).
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Paecilomyces hepiali mycelium culture extract CBG-CS-2 (Chebeigen, Korea) | Adenosine | 0.13 percent of extract (mycelium culture extract) | reported value (reported) | not stated. one product, one manufacturer or one purchased sample |
Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Comp... (1 value)
Source: Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Complement Altern Med 2019;19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6441223/. Open access; values as cited by the authors from earlier work. Laboratory: Korean manufacturer's analysis, reported in the paper. Method: HPLC per Korean food regulator guidelines, as stated. Date: 2019 paper (maker's earlier work cited).
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Paecilomyces hepiali mycelium culture extract CBG-CS-2 (Chebeigen, Korea) | Cordycepic acid | 7.3 percent of extract (mycelium culture extract) | reported value (reported) | not stated. one product, one manufacturer or one purchased sample |
Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Comp... (1 value)
Source: Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Complement Altern Med 2019;19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6441223/. Open access; values as cited by the authors from earlier work. Laboratory: Korean manufacturer's analysis, reported in the paper. Method: HPLC per Korean food regulator guidelines, as stated. Date: 2019 paper (maker's earlier work cited).
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Paecilomyces hepiali mycelium culture extract CBG-CS-2 (Chebeigen, Korea) | Extract powder share of test capsule | 85.36 percent of capsule contents (capsule composition) | reported value (reported) | not stated. one product, one manufacturer or one purchased sample |
Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Comp... (1 value)
Source: Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Complement Altern Med 2019;19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6441223/. Open access; values as cited by the authors from earlier work. Laboratory: Korean manufacturer's analysis, reported in the paper. Method: HPLC per Korean food regulator guidelines, as stated. Date: 2019 paper (maker's earlier work cited).
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Paecilomyces hepiali mycelium culture extract CBG-CS-2 (Chebeigen, Korea) | Cordycepin | 0.001 percent of extract (mycelium culture extract) | reported value (reported) | not stated. one product, one manufacturer or one purchased sample |
Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Comp... (1 value)
Source: Jung SJ et al. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2). BMC Complement Altern Med 2019;19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6441223/. Open access; values as cited by the authors from earlier work. Laboratory: Korean manufacturer's analysis, reported in the paper. Method: HPLC per Korean food regulator guidelines, as stated. Date: 2019 paper (maker's earlier work cited).
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Paecilomyces hepiali mycelium culture extract CBG-CS-2 (Chebeigen, Korea) | Cordyceps polysaccharide | 32 percent of extract (mycelium culture extract) | reported value (reported) | not stated. one product, one manufacturer or one purchased sample |
What is Cs-4 and cultured Cordyceps mycelium good for?
What the body uses it for, and how strong the evidence is. A normal job in the body is not proof that extra supplements add benefit; each card says which.
Kidney function markers (as an add-on in kidney disease)
Preliminary or mixedChinese trials of Jinshuibao (fermented Cs-4) added to usual care report lower urea and creatinine and, in diabetic kidney disease, lower urine protein.
Supplements: Surrogate-marker signals only; low to moderate certainty; not a replacement for treatment.
Lung function in stable COPD (as an add-on)
Preliminary or mixedA pooled analysis of 23 Chinese trials found better lung-function numbers when Jinshuibao was added to usual COPD care.
Supplements: Low-quality evidence; not shown for Cs-4 products sold outside China.
Symptoms after COVID-19
Preliminary or mixedA 200-person double-blind pilot found more improvement in cough, breathlessness, sweating, chest tightness and palpitation with Jinshuibao than with placebo over two weeks.
Supplements: Pilot only.
Immune markers (natural killer cell activity)
Preliminary or mixedIn 79 healthy adults, a P. hepiali mycelium extract raised natural killer cell activity versus placebo over 8 weeks.
Supplements: Biomarker change only; no illness outcome tested.
Exercise capacity
Preliminary or mixedA 20-person pilot of Cs-4 in older adults reported a higher metabolic threshold; a 22-person trial in trained cyclists found no change in performance.
Supplements: Not reliably shown.
As a food (nutrition)
Preliminary or mixedCs-4 mycelium is an ingredient in capsules and tablets, not a food, and no nutrient table exists for it.
Supplements: Not applicable: no food role has been shown.
Not the wild fungus and not Bailing
Preliminary or mixedCs-4 is Paecilomyces hepiali grown in tanks; Bailing is Hirsutella sinensis; the wild caterpillar fungus is Ophiocordyceps sinensis.
Supplements: Results do not transfer between the wild fungus, Bailing, Jinshuibao and C. militaris products.
Connected topics
Open a group to see how each topic connects and how strong the evidence is.
Health goals (3)
- Lung SupportPreliminary or mixed
Pooled Chinese trials found better lung-function numbers with Jinshuibao added to COPD care, but the trials were low quality and the authors could not confirm efficacy and safety.
- Breathing SupportPreliminary or mixed
Breathlessness and cough improved more with Jinshuibao than placebo in one 200-person post-COVID pilot; COPD trials were low quality.
- Immune SupportPreliminary or mixed
A Korean P. hepiali extract raised natural killer cell activity in 79 healthy adults; no infection or illness outcome was tested.
Body systems (6)
- Kidney & UrinaryPreliminary or mixed
Chinese trials of Jinshuibao added to usual care report lower urea, creatinine and urine protein; trials were low quality and the markers are not hard outcomes.
- Respiratory HealthPreliminary or mixed
Pooled Chinese trials found better lung-function numbers with Jinshuibao added to COPD care, but the trials were low quality and the authors could not confirm efficacy and safety.
- Respiratory SystemPreliminary or mixed
Pooled Chinese trials found better lung-function numbers with Jinshuibao added to COPD care, but the trials were low quality and the authors could not confirm efficacy and safety.
- Urinary SystemPreliminary or mixed
Chinese trials of Jinshuibao added to usual care report lower urea, creatinine and urine protein; trials were low quality and the markers are not hard outcomes.
- Immune SupportPreliminary or mixed
A Korean P. hepiali extract raised natural killer cell activity in 79 healthy adults; no infection or illness outcome was tested.
- Immune SystemPreliminary or mixed
A Korean P. hepiali extract raised natural killer cell activity in 79 healthy adults; no infection or illness outcome was tested.
Body parts (2)
- KidneysPreliminary or mixed
Chinese trials of Jinshuibao added to usual care report lower urea, creatinine and urine protein; trials were low quality and the markers are not hard outcomes.
- LungsPreliminary or mixed
Pooled Chinese trials found better lung-function numbers with Jinshuibao added to COPD care, but the trials were low quality and the authors could not confirm efficacy and safety.
Functional actions (2)
- Respiratory SupportPreliminary or mixed
Pooled Chinese trials found better lung-function numbers with Jinshuibao added to COPD care, but the trials were low quality and the authors could not confirm efficacy and safety.
- Immune ModulationPreliminary or mixed
A Korean P. hepiali extract raised natural killer cell activity in 79 healthy adults; no infection or illness outcome was tested.
Root causes (1)
- Medication Side EffectsDocumented risk
Cordyceps in general may add to blood-thinner and blood-sugar medicines (lab studies, MSK); not tested for Cs-4.
Biomarkers (1)
- CreatininePreliminary or mixed
Serum creatinine was lower with Jinshuibao added to usual treatment in pooled Chinese trials; low-quality trials, and a lower value does not by itself prove kidney benefit.
Conditions & symptoms (4)
- Chronic Kidney InsufficiencyPreliminary or mixed
Jinshuibao added to usual care lowered urea and creatinine in pooled Chinese trials; low quality, blood markers only.
- Chronic Obstructive Airway DiseasePreliminary or mixed
23 Chinese trials (1,932 people) of Jinshuibao added to usual COPD care showed better lung-function numbers; quality low, safety not confirmable.
- Diabetic NephropathyPreliminary or mixed
An umbrella review of 157 trials found lower urine protein when fungal capsules were added to standard drugs; most trials had some concerns about bias. One earlier Jinshuibao meta-analysis was retracted and is not used.
- Kidney Failure, ChronicPreliminary or mixed
A 17-trial meta-analysis (1,431 people) reported better kidney blood markers with Jinshuibao added to conventional treatment; authors ask for high-quality trials.
Documented risks and interactions (4)
- Possible medicine interactions (blood thinners, blood-sugar drugs). MSK says lab studies suggest cordyceps may add to blood-thinner and blood-sugar medicine effects, and reports one bleeding case.
- Bone-marrow (myelogenous) cancers. MSK advises that people with myelogenous-type cancers should not use cordyceps, based on animal findings.
- Safety data in trials are thin. Trials report few mild side effects (headache, nausea, vomiting, insomnia, mild abdominal discomfort), but most did not report adverse events in detail and none was large or long.
- Mislabelling and adulteration risk for 'Cordyceps' products. A 2026 survey of 65 online Cordyceps supplements in Thailand found 54.3% falsified and 6.2% containing corticosteroids.
The short version. "Cs-4" is the name of one fungus strain, now called Paecilomyces hepiali, that scientists first isolated from wild caterpillar fungus in the early 1980s and that factories now grow in tanks as mycelium (the thread-like body of a fungus). [1] It is the fungus inside the Chinese medicine Jinshuibao and inside several "Cordyceps" supplements, including products sold in the West under the Cs-4 name. [1][12] It is not the wild caterpillar fungus, and it is not the fungus that Bailing capsules are made from. [1] Most of the human research is on Jinshuibao, mostly in China, mostly in kidney and lung patients, and the trials are small and of low quality. Reviews that pool them find signals on blood tests, not proof of health benefit. [4][5][6] Two small Western exercise trials of Cs-4 pointed in opposite directions. [9][10]
What it is, and what it is not
The wild "caterpillar fungus" is Ophiocordyceps sinensis, described on our caterpillar fungus page. When Chinese scientists tried to grow fungi from it in the 1970s and 1980s, they isolated several. [1] One of them, a strain named Cs-4, became Paecilomyces hepiali (the 1982 description). [1] A 2015 industry review makes three points that matter to a shopper. [1]- P. hepiali was first described as the "anamorph" (the asexual form) of the wild fungus, but that description was not validly published. A different fungus, Hirsutella sinensis, is the one mycologists generally accept as the asexual form of O. sinensis. [1]
- The review states that P. hepiali is not the anamorph of O. sinensis, but belongs to the same broad group of cordyceps fungi. [1] The authors treat it as an independent cordyceps fungus rather than a cultured copy of the wild one. [1]
- Bailing capsules (also called Corbrin) are made by fermenting Hirsutella sinensis, a different organism from Cs-4. Jinshuibao is made by fermenting Cs-4 (P. hepiali). [1] A third fungus, Mortierella hepiali, goes into Zhiling capsules. [1]
So three different organisms are sold under the one word "Cordyceps", and all three are different from the wild fungus. Our page on the species question covers the other common mix-up, between Cordyceps militaris and O. sinensis.
Two separate questions: food and supplement
As a food. Cs-4 mycelium is not a food. It is an ingredient in capsules, tablets and powders. USDA FoodData Central has no record for it, and we found no open measured values for protein, vitamins or minerals in it. Proper evidence not found for a food-nutrition role.As a supplement or medicine. In China, Jinshuibao capsules and tablets are sold as a regulated medicine. A 2015 review says they were approved by the national new-drug committee in 1989 and are used for conditions that include lung and kidney weakness, chronic cough, chronic bronchitis, chronic kidney insufficiency, fatigue and high blood fats. [1] That is the regulatory and traditional-medicine label: it describes how the product is positioned in China, not what trials prove. Outside China, Cs-4 products are sold as supplements, and a 2026 review notes that supplement products there typically use cultured mycelium (the "Cs-4" strain) rather than the wild fungus. [12]
Fruiting body versus mycelium
Cs-4 products are mycelium grown by fermentation, not a fruiting body and not mycelium grown on grain. [1] Fermentation in liquid gives a product that is mostly fungal biomass and its extracts, so it does not carry the leftover grain starch that mycelium-on-grain powders do. A 2025 review of caterpillar-fungus cultivation says fermented mycelium has a chemical profile distinct from the wild fungus. [12] See fruiting body versus mycelium and mycelium on grain. The practical point is the same one that runs through this site: a result from one form (here, tank-grown P. hepiali) does not transfer to the wild fungus, to Bailing, or to C. militaris products.Traditional use
Traditional use only, not proof. Cs-4 is a modern, factory-made product, so it has no centuries-long history of its own; its reputation is borrowed from the wild fungus, which MSK says is used in traditional Chinese medicine for fatigue, sexual dysfunction and cough. [2] The Jinshuibao drug label lists a long set of uses (see above), which come from that tradition. [1] A tradition or a drug label is not evidence that a product works.What research shows
The table says which product was tested, because that decides what a result can tell you.| Use | What the source found | Strength of evidence | Product, population |
|---|---|---|---|
| Stable COPD (a chronic lung disease) | A 2024 meta-analysis of 23 randomised trials (1,932 people, all in China) found better lung-function numbers (for example FEV1% predicted) when Jinshuibao was added to usual care. The authors say the studies were of low quality (none described blinding or hidden allocation), the results varied a great deal between trials, and efficacy and safety "could not be reliably confirmed". [4] | Preliminary, low quality | Jinshuibao capsules added to usual COPD treatment |
| Chronic kidney failure | A 2023 meta-analysis of 17 trials (1,431 people) reported lower blood urea and creatinine and better albumin and haemoglobin with Jinshuibao added to usual treatment. The authors call for high-quality trials. [5] | Preliminary: blood-test measures, not kidney failure or survival | Jinshuibao added to conventional treatment |
| Diabetic kidney disease | A 2024 umbrella review pooled 157 trials (13,143 people) of fungal capsules added to standard drugs for diabetic kidney disease. Almost all trials had "some concerns" about bias. Adding these capsules was linked with lower urine protein; for Jinshuibao the authors report moderate-certainty benefit for urine protein, creatinine, urea and blood glucose. [6] | Preliminary: blood and urine measures; the authors call for better trials | Jinshuibao and Bailing/Zhiling products, added to RAS-blocker drugs |
| Kidney injury after X-ray contrast dye | A 2024 review of 14 trials (1,271 people) of fermented fungal products (Bailing, Zhiling and Jinshuibao) found fewer cases of kidney injury (14.6% vs 5.4%), with "low certainty" and a call for placebo-controlled trials. The benefit was clear for Bailing and Jinshuibao but not for Zhiling. [7] | Low certainty | Three fermented products; not Cs-4 alone |
| Symptoms after COVID-19 | A pilot trial of 200 people recovering from COVID-19 (double-blind, placebo-controlled, two weeks) found higher rates of improvement in dry cough, breathlessness, sweating, chest tightness and palpitation with Jinshuibao than with placebo; no severe adverse events were reported. [8] | Preliminary: a pilot, short, patient-reported | Jinshuibao capsules, China |
| Immune markers in healthy adults | In 79 healthy adults, natural killer cell activity rose more over 8 weeks with a P. hepiali mycelium extract than with placebo; no serious adverse events were reported. [11] | Biomarker change only; no illness outcome | A Korean P. hepiali extract (CBG-CS-2), not the Jinshuibao product |
| Exercise in healthy older adults | A 12-week double-blind pilot of Cs-4 (20 people aged 50 to 75) reported a 10.5% higher metabolic threshold; maximal oxygen uptake did not change in either group. [9] | Promising but a small pilot | Cs-4 capsules, 333 mg three times a day |
| Exercise in trained cyclists | In 22 trained male cyclists, 5 weeks of CordyMax Cs-4 tablets did not change peak oxygen uptake, ventilatory threshold or time-trial performance. [10] | No benefit shown in this trial | CordyMax Cs-4 tablets, 3 g a day |
How to read this. The Chinese reviews are consistent in direction but weak in quality: open-label or unblinded, short, done in one country, and often judged by blood and urine tests rather than by outcomes such as dialysis or death. [4][5][6][12] A 2026 review of caterpillar-fungus products concludes that this body of work does not meet the European Medicines Agency's standard for "well-established use". [12] The one head-to-head Western exercise pair (positive pilot, null trial) is a good reminder of how small the Western evidence is; see cordyceps for energy and exercise. One earlier Jinshuibao meta-analysis in diabetic nephropathy (2022) has been retracted by its journal, and we do not rely on it. [15]
We also saw that one 2026 review lists a long-COVID fatigue trial of Cs-4 (110 people, waitlist-controlled) with improvement in fatigue and quality of life. [12] We did not open the trial itself, so we mention it only as reported by the review; a waitlist comparison is not a placebo.
Forms you may see
- Jinshuibao capsules and tablets. The Chinese medicine made by fermenting Cs-4; the form in most Chinese trials. [1][4][5]
- Cs-4 capsules or tablets under supplement brand names. Used in the two US exercise trials; the label may say Cordyceps sinensis even though the organism is the cultured Cs-4 strain. [9][10][12]
- **Other P. hepiali mycelium extracts** (for example the Korean CBG-CS-2). Same species, different strain, different process; the immune trial used this. [11]
- Blends. Cs-4 may appear in multi-mushroom products, where the amount of each ingredient is often not stated. See single species versus blends.
Lab data and chemistry
This section is for readers who want to see what laboratories have measured. It does not show that Cs-4 does anything in people. Wikidata (the open knowledge base behind the LOTUS natural-products project) lists no compounds for Paecilomyces hepiali (Q10614990). [14] It does list 112 compounds for Hirsutella sinensis (Q398300), the fungus in Bailing, but none of those statements carries a paper reference in our extract and they describe a different organism, so we do not use that list for Cs-4. [14] The compound table below therefore rests on papers we opened.A. What the laboratory literature reports in this fungus
| Compound or group | Class | Where in the mushroom / form | Identity | Source |
|---|---|---|---|---|
| Cordyceps polysaccharides | Fibre-like carbohydrate chains | Mycelium culture extract of P. hepiali (CBG-CS-2); the authors report 32% | not single compounds | [11] |
| Cordycepic acid | Acid-type constituent named in the cordyceps literature; we did not verify its exact chemistry | Same extract; the authors report 7.3% | not single compounds | [11] |
| Adenosine | Nucleoside | Same extract; the authors report 0.13% | ChEBI 16335 | [11] |
| Cordycepin (3'-deoxyadenosine) | Nucleoside | Same extract; the authors report 0.001%, i.e. almost none | ChEBI 29014 | [11] |
| Organic acids, lipids and lipid-like molecules, organoheterocyclic compounds | Broad metabolite groups | Dried Jinshuibao (P. hepiali) bought from a pharmacy; the main groups of differing metabolites in an untargeted screen | not single compounds | [3] |
| Amino acids (for example glutamic acid, L-arginine, L-histidine) | Protein building blocks | Found in all three fungi of that study, including the P. hepiali sample | not single compounds | [3] |
| Fatty acids and fatty-acid amides (for example oleic acid, palmitic acid, oleamide) | Lipids | Found in all three samples | not single compounds | [3] |
| Antioxidant capacity | Test-tube assay, not a compound | Dried Jinshuibao: highest FRAP of the three samples | not applicable | [3] |
Cordycepin, the compound most quoted for C. militaris, is reported at 0.001% in the P. hepiali extract above, so Cs-4 is not a cordycepin product. [11] Our page on cordycepin explains the compound.
B. Measured values
USDA FoodData Central has no record for Cs-4 or P. hepiali, so there are no USDA food values. We found no open measured value for ergothioneine, vitamin D, enzymatic beta-glucan, total triterpenes, arsenic or other metals in Cs-4 or Jinshuibao. The rows below are all we could find; each comes from one product.
| Measure | Value | Basis | Sample | Source |
|---|---|---|---|---|
| Cordyceps polysaccharide | 32% | In the mycelium culture extract, by HPLC (as reported by the authors, citing earlier work by the same group) | P. hepiali extract CBG-CS-2, Korean manufacturer | [11] |
| Cordycepic acid | 7.3% | Same | Same | [11] |
| Adenosine | 0.13% | Same | Same | [11] |
| Cordycepin | 0.001% | Same | Same | [11] |
| Share of extract powder in the test capsule | 85.36% of capsule contents | Capsule composition | Same | [11] |
| FRAP total antioxidant capacity | 8.26 micromole Trolox per g | Dried powder; test-tube assay | Jinshuibao (P. hepiali) bought from pharmacies, one sample | [3] |
C. What the numbers do and do not mean
- One product is not "Cs-4". The composition figures come from one Korean P. hepiali extract, which is a different strain and process from Jinshuibao or from US supplements sold under the Cs-4 name. Another maker's product could differ. [11]
- Compound percentages depend on the method. "Cordyceps polysaccharide" is a total-carbohydrate type measure, not the same as an enzymatic beta-glucan measure; see beta-glucans versus polysaccharides. A "standardised to polysaccharide" label says little about specific actives. [11]
- A test-tube antioxidant score is not a health effect. The FRAP number comes from one pharmacy sample and a laboratory assay. [3]
- Cs-4 is not a copy of the wild fungus. A study comparing wild cordyceps with Bailing and Jinshuibao samples found the metabolite profiles differed in several groups (for example the wild sample was richer in lipids and the P. hepiali sample in organic acids). Treat each as a different material. [3]
- Purity and metals are unmeasured here. Without an open measurement for arsenic or other metals in Cs-4 products, ask a seller for a certificate of analysis; see mushroom testing and certificates of analysis.
Related pages
Cordyceps overview, caterpillar fungus (Ophiocordyceps sinensis), Cordyceps militaris versus Ophiocordyceps sinensis, cordyceps for energy and exercise, cordyceps side effects and medicine cautions.Frequently asked questions
What is Cs-4?
Cs-4 is a strain of the fungus Paecilomyces hepiali, first isolated from wild caterpillar fungus and now grown in tanks as mycelium. It is the fungus in Jinshuibao and in several supplements sold under the Cs-4 name. [1]
Is Cs-4 the same as the wild caterpillar fungus?
No. A 2015 review says P. hepiali is not the asexual form of the wild fungus, and treats it as a separate cordyceps fungus. [1]
Is Cs-4 the same as Bailing capsules?
No. Bailing is made from Hirsutella sinensis and Jinshuibao from Cs-4 (P. hepiali). [1]
Does Cs-4 help the kidneys or lungs?
Pooled Chinese trials of Jinshuibao found better blood and breathing-test numbers when it was added to usual treatment, but the trials were small, unblinded and of low quality, and the authors ask for better ones. [4][5][6]
Does Cs-4 improve exercise?
Not reliably. A small pilot in older adults found higher thresholds and a trial in trained cyclists found no change. [9][10]
Is it safe?
Trials report few mild side effects, but most did not report them in detail and none was large. Cordyceps in general may interact with blood thinners and blood-sugar medicines, per MSK, though we found no Cs-4 test of that. [2][4]
How do I know what is in the bottle?
You usually cannot from the label. A 2026 survey found over half of 65 online "Cordyceps" products falsified. Ask for a certificate of analysis. [13]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Safety and limits of the evidence
- What the trials reported. The Jinshuibao COPD review found few adverse events: mild headache, nausea, vomiting, insomnia and mild abdominal discomfort in a few people in three studies, all resolved on their own. But most trials did not report adverse events in detail, so the authors say safety cannot be concluded. [4] The post-COVID pilot and the Korean immune trial reported no severe or serious adverse events. [8][11] The contrast-dye review found no significant difference in adverse events. [7] The umbrella review of diabetic kidney disease reported no serious adverse events. [6] None of these trials was large or long enough to detect rare harms.
- Medicines. MSK discusses cordyceps in general (its studies did not separate species or products). It says laboratory studies suggest cordyceps may add to the effect of blood-sugar medicines and may increase the effect of blood thinners such as warfarin (raising bleeding risk), and it reports one case of heavy bleeding after a tooth extraction in a daily user. [2] These cautions come from cordyceps in general, and we found no source that tests Cs-4 on them; treat them as a reason to ask, not as proof either way. See cordyceps side effects and medicine cautions, medication interactions and surgery and bleeding.
- Blood cancers. MSK says people with myelogenous (bone-marrow) type cancers should not use cordyceps, based on animal findings. [2]
- Immune-suppressing medicines and transplants. Kidney patients in the trials took Cs-4-type products as an add-on under medical care. We found no source on whether they interact with transplant drugs, so talk to the transplant team before taking one. See autoimmune conditions and transplants.
- Pregnancy, breastfeeding, children. MSK does not address pregnancy, and we found no Cs-4 source for pregnancy, breastfeeding or children. That is not proof of safety. See pregnancy and breastfeeding with mushroom supplements.
- Metals. Wild caterpillar fungus is known for high total arsenic (see our caterpillar fungus page). A 2026 review states that cultured mycelium avoids this concern. [12] We found no open measurement of arsenic or other metals in Jinshuibao or Cs-4 products themselves, so we cannot give a number. See heavy metals and contamination.
- Quality and mislabelling. A 2026 survey of 65 "Cordyceps" supplements sold online in Thailand found 54.3% falsified (for example C. militaris sold as C. sinensis, or none of the labelled species), and 6.2% adulterated with corticosteroids. [13] The survey did not target Cs-4 products, but it shows why "Cordyceps" on a label is not a reliable description. See supplement adulteration and how to read a label.
- Regulation. In China, Jinshuibao has medicine status (see above). [1] In the US, mushroom products are sold as dietary supplements; see are mushroom supplements regulated?.
References
- Dong C, Guo S, Wang W, Liu X. Cordyceps industry in China. Mycology 2015;6. Open access, full text read 2026-10-24.
- Memorial Sloan Kettering Cancer Center, Cordyceps, About Herbs (page last updated 2022-02-10). Read 2026-10-24. The page covers cordyceps in general, not Cs-4 specifically.
- He M, Tang CY, Wang T, Xiao MJ, Li YL, Li XZ. Analysis of metabolic profiles and antioxidant activity of Chinese cordyceps, Ophiocordyceps sinensis, and Paecilomyces hepiali based on untargeted metabolomics. Biology (Basel) 2024. Open access, full text read 2026-10-24.
- Yin Y, Wang Y, Liu Y, Wang F, Wang Z. Evidence construction of Jinshuibao capsules against stable chronic obstructive pulmonary disease: a systematic review and network pharmacology. Heliyon 2024;10. Open access, full text read 2026-10-24.
- Zhang H, Ma Y, Sun C, Zhang Q. Efficacy of Jinshuibao as an adjuvant treatment for chronic renal failure in China: a meta-analysis. Medicine (Baltimore) 2023;102. Open access, abstract and results read 2026-10-24.
- Xue X et al. Ophiocordyceps sinensis preparations combined with the renin-angiotensin system inhibitor for diabetic kidney disease treatment: an umbrella review of systematic reviews and network meta-analysis. Front Pharmacol 2024. Abstract read via Europe PMC 2026-10-24.
- Pu F et al. Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials. Ren Fail 2024. Abstract read via Europe PMC 2026-10-24.
- Yuehong Z et al. Effectiveness and safety of Jinshuibao capsules in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-controlled clinical trial. J Tradit Chin Med 2023;43. Abstract read 2026-10-24.
- Chen S, Li Z, Krochmal R, Abrazado M, Kim W, Cooper CB. Effect of Cs-4 (Cordyceps sinensis) on exercise performance in healthy older subjects: a double-blind, placebo-controlled trial. J Altern Complement Med 2010. Abstract read via Europe PMC 2026-10-24.
- Parcell AC, Smith JM, Schulthies SS, Myrer JW, Fellingham G. Cordyceps sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance. Int J Sport Nutr Exerc Metab 2004. Abstract read via Europe PMC 2026-10-24.
- Jung SJ, Jung ES, Choi EK, Sin HS, Ha KC, Chae SW. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trial. BMC Complement Altern Med 2019;19. Open access, full text read 2026-10-24.
- Panossian A. Pleiotropic bioactivity of caterpillar fungus, orange cordyceps, and cordycepin: insight from integrated network pharmacology and food and drug regulatory analysis. Pharmaceuticals (Basel) 2026;19. Open-access review; the sections on preparations, regulation, safety and the trial tables read 2026-10-24.
- Wirasathien L, Sriputhon N, Tangkiatkumjai M. Post-marketing surveillance of cordyceps products online: identifying falsified products and regulatory challenges. BMC Complement Med Ther 2026. Open access, abstract and introduction read 2026-10-24.
- Wikidata (CC0), compound-in-taxon statements (property P703) for Paecilomyces hepiali (Q10614990, no compounds listed) and Hirsutella sinensis (Q398300, 112 compounds, no paper references in our extract), the data used by the LOTUS initiative; retrieved 2026-10-23 from the project's source file.
- Retraction notice: Efficacy and Safety of Jinshuibao Capsule in Diabetic Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (retracts Comput Math Methods Med 2022, DOI 10.1155/2022/9671768). Notice read via Europe PMC 2026-10-24.